WES AMYOTROPHIC LATERAL SCLEROSIS, ALS DG 3.8.1

Gene	Twist X2 covered >10x	Twist X2 covered >20x	WGS covered >10x	WGS covered >20x	Associated Phenotype description and OMIM disease ID
ALS2	100.0%	100.0%	100.0%	99.2%	Primary lateral sclerosis, juvenile, 606353;Spastic paralysis, infantile onset ascending, 607225;Amyotrophic lateral sclerosis 2, juvenile, 205100
ANG	100.0%	100.0%	100.0%	100.0%	Amyotrophic lateral sclerosis 9, 611895
ANXA11	100.0%	100.0%	100.0%	99.8%	Amyotrophic lateral sclerosis 23, 617839;Inclusion body myopathy and brain white matter abnormalities, 619733
CFAP410	100.0%	100.0%	100.0%	99.9%	Retinal dystrophy with macular staphyloma, 617547;Spondylometaphys eal dysplasia, axial, 602271
CHCHD10	100.0%	100.0%	100.0%	99.2%	?Myopathy, isolated mitochondrial, autosomal dominant, 616209;Spinal muscular atrophy, Jokela type, 615048;Frontotemporal dementia and/or amyotrophic lateral sclerosis 2, 615911
СНМР2В	100.0%	100.0%	100.0%	98.1%	Frontotemporal dementia and/or amyotrophic lateral sclerosis 7, 600795
ERBB4	100.0%	99.9%	100.0%	99.6%	Amyotrophic lateral sclerosis 19, 615515

FIG4	100.0%	100.0%	100.0%	99.5%	Yunis-Varon syndrome, 216340;?Polymicrogyria, bilateral temporooccipital, 612691;Amyotrophic lateral sclerosis 11, 612577;Charcot-Marie- Tooth disease, type 4J, 611228
FUS	100.0%	100.0%	100.0%	99.7%	Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia, 608030;Essential tremor, hereditary, 4, 614782
GRN	100.0%	100.0%	100.0%	99.8%	Aphasia, primary progressive, 607485; Frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485; Ceroid lipofuscinosis, neuronal, 11, 614706
KIF5A	100.0%	100.0%	100.0%	98.9%	Myoclonus, intractable, neonatal, 617235;{Amyotrophic lateral sclerosis, susceptibility to, 25}, 617921;Spastic paraplegia 10, autosomal dominant, 604187
MAPT	100.0%	100.0%	100.0%	99.6%	Supranuclear palsy, progressive, 601104;Supranuclear palsy, progressive atypical, 260540;Dementia, frontotemporal, with or without parkinsonism, 600274;{Parkinson disease, susceptibility to}, 168600;Pick disease, 172700
MATR3	100.0%	100.0%	100.0%	98.9%	Amyotrophic lateral sclerosis 21, 606070
NEK1	100.0%	100.0%	100.0%	99.1%	Short-rib thoracic dysplasia 6 with or without polydactyly, 263520;?Orofaciodigital syndrome II, 252100;{Amyotrophic lateral sclerosis, susceptibility to, 24}, 617892

OPTN	100.0%	100.0%	100.0%	99.5%	Glaucoma 1, open angle, E, 137760; Amyotrophic lateral sclerosis 12 with or without frontotemporal dementia, 613435; Glaucoma, normal tension, susceptibility to}, 606657
PFN1	100.0%	100.0%	100.0%	98.9%	Amyotrophic lateral sclerosis 18, 614808
SETX	100.0%	100.0%	100.0%	99.2%	Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2, 606002;Amyotrophic lateral sclerosis 4, juvenile, 602433
SIGMAR1	100.0%	100.0%	100.0%	100.0%	?Neuronopathy, distal hereditary motor, autosomal recessive 2, 605726;?Amyotrophic lateral sclerosis 16, juvenile, 614373
SOD1	100.0%	100.0%	100.0%	99.8%	Spastic tetraplegia and axial hypotonia, progressive, 618598;Amyotrophic lateral sclerosis 1, 105400
SPG11	100.0%	100.0%	100.0%	99.3%	Amyotrophic lateral sclerosis 5, juvenile, 602099;Charcot-Marie- Tooth disease, axonal, type 2X, 616668;Spastic paraplegia 11, autosomal recessive, 604360
SQSTM1	100.0%	100.0%	100.0%	99.7%	Neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset, 617145;Frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437;Myopathy, distal, with rimmed vacuoles, 617158;Paget disease of bone 3, 167250
TARDBP	100.0%	100.0%	100.0%	99.5%	Frontotemporal lobar degeneration, TARDBP- related, 612069;Amyotrophic lateral sclerosis 10, with or without FTD, 612069

TBK1	100.0%	100.0%	100.0%	99.2%	{Encephalopathy, acute, infection-induced (herpesspecific), susceptibility to, 8}, 617900; Frontotemporal dementia and/or amyotrophic lateral sclerosis 4, 616439
TUBA4A	100.0%	100.0%	100.0%	99.9%	Amyotrophic lateral sclerosis 22 with or without frontotemporal dementia, 616208
UBQLN2	100.0%	100.0%	99.0%	70.9%	Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857
VAPB	100.0%	100.0%	100.0%	99.5%	Spinal muscular atrophy, late-onset, Finkel type, 182980;Amyotrophic lateral sclerosis 8, 608627
VCP	100.0%	100.0%	100.0%	99.3%	Frontotemporal dementia and/or amyotrophic lateral sclerosis 6, 613954;Charcot-Marie- Tooth disease, type 2Y, 616687;Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1, 167320

Gene symbols used follow HGCN guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan 43(Database issue):D1079-85.

TWIST X2 Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WES using TWIST X2 chemistry.

TWIST X2 Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WES using TWIST X2 chemistry.

srWGS GRCh38 Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WGS mapped against GRCh38.

srWGS GRCh38 Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WGS mapped against GRCh38.

non-protein coding genes are covered, but as coverage statistics are based on protein coding regions, statistics could not be generated.

OMIM release used for OMIM disease identifiers and descriptions: March 17th, 2023.

This list is accurate for panel version DG 3.7.0.

EAS.GenProductCoverage.pdf.footer.ad01